Dana Goldman holds the Leonard D. Schaeffer Chair and is a Distinguished Professor of Pharmacy, Public Policy, and Economics at the University of Southern California. He also directs the Schaeffer Center for Health Policy and Economics, one of the nation’s premier health policy research institutions. Dr. Goldman is the author of over 200 articles and book chapters. He is a health policy advisor to the Congressional Budget Office, the Fred Hutchinson Cancer Institute, and several health care companies. He also serves on the editorial boards of Health Affairs and the American Journal of Managed Care, and is founding editor of the Forum for Health Economics and Policy. His work has been featured in the New York Times, Wall Street Journal, Washington Post, Business Week, The Economist, NBC Nightly News, CNN and other media. Dr. Goldman is an elected member of the National Academy of Medicine, one of the highest health policy honors. Dr. Goldman received his B.A. summa cum laude from Cornell University and a Ph.D. in Economics from Stanford University.

Recent Posts by Dana Goldman

Follow The Money: The Flow Of Funds In The Pharmaceutical Distribution System

Publicly traded companies in the pharmaceutical distribution system must disclose annual financial information to the SEC. Those reports provide some of the most reliable public information about how funds flow through the distribution system.

Rapid Biomedical Innovation Calls For Similar Innovation In Pricing And Value Measurement

Between 1980 and 2010, overall personal health care expenditures in the US grew nearly four-fold, driven in part by new technologies. What---if anything---should be done to regulate this innovation?

September 15, 2016Drugs and Medical Innovation

Does A ‘One-Size-Fits-All’ Formulary Policy Make Sense?

The rapid growth in the use of step therapy policies in recent years---from 27 percent in 2005 to 73 percent in 2013 among employers---indicates a misunderstanding about the direct and indirect harms of this approach.

Moving Beyond Price-Per-Dose In The Pharmaceutical Industry

Hundreds of thousands of deaths, heart attacks, and strokes have been prevented due to lower cholesterol, yet many patients are missing out on lipid-lowering therapies. Our outdated "price-per-dose" model of pharmaceutical pricing limits access and produces a number of well-known side effects...

It’s Time For Value-Based Payment In Oncology

Value-based health care has risen to the top of the health policy agenda, as public and private payers search for ways to improve outcomes. It’s time to apply this principle in oncology.

Mortality Versus Survival In International Comparisons Of Cancer Care

In a recent paper, Soneji and Yang revisit a topic we first explored in the April 2012 issue of Health Affairs -- namely, whether the U.S. gets value for its cancer care. We found that life expectancy after cancer diagnosis rose more quickly for patients in the U.S. than for patients in Europe....

Why ‘Medicare-For-All’ Is Not The Answer

The Affordable Care Act survived the Supreme Court and a presidential election, so why does it face such an uncertain future? One reason is that it was essentially silent on how to control costs. This has led many pundits -- including the likes of Paul Krugman and Robert Reich -- to argue...

Harnessing The Promise Of Comparative Effectiveness Research

The Federal Government has made an unprecedented effort to publicly finance research on the effectiveness of medical treatments.  The Patient Protection and Affordable Care Act of 2010 established both the Patient-Centered Outcomes Research Institute and the Center for Medicare and Medicaid...

When Epidemiology Goes Astray: Valuing Cancer Care In The United States And Europe

In a recent Health Affairs paper, we documented that the United States has a significant survival advantage over much of Europe when it comes to cancer: 1.8 years for those diagnosed during our study window.  Furthermore, we showed over a 17-year period that this gap had widened, not narrowed,...

Saving Medicare Dollars: Moving From The SGR To Bundled Payments

Editor’s note:  The ideas expressed in this post draw on the “IPAB Working Group,” a panel of health care experts supported by Pfizer and charged with identifying strategies the Independent Payment Advisory Board might use to lower Medicare spending. Though many of the ideas that follow...